<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093663</url>
  </required_header>
  <id_info>
    <org_study_id>SPD476-319</org_study_id>
    <secondary_id>2013-001744-65</secondary_id>
    <nct_id>NCT02093663</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis</brief_title>
  <acronym>PACE</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      To assess clinical response to MMX mesalamine/mesalazine between a low and high dose in
      children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or who
      are in remission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2014</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>8 weeks (Acute Phase)</time_frame>
    <description>Partial Ulcerative Colitis Disease Activity Index (UC-DAI) Score. This assessment was done without endoscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance of Clinical Response</measure>
    <time_frame>26 weeks (Maintenance Phase)</time_frame>
    <description>Partial Ulcerative Colitis Disease Activity Index (UC-DAI) Score. This assessment was done without endoscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and Endoscopic Response</measure>
    <time_frame>8 weeks (Acute Phase) and 26 weeks (Maintenance Phase)</time_frame>
    <description>Full UC-DAI Score. This assessment was done with endoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Signs and Symptoms of Mild to Moderate Ulcerative Colitis</measure>
    <time_frame>8 weeks (Acute Phase) and 26 weeks (Maintenance Phase)</time_frame>
    <description>Daily Ulcerative Colitis Scale (DUCS) Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Mild to Moderate Ulcerative Colitis</measure>
    <time_frame>8 weeks (Acute Phase)</time_frame>
    <description>Pediatric Ulcerative Colitis Activity Index (PUCAI) Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission</measure>
    <time_frame>26 weeks (Maintenance Phase)</time_frame>
    <description>PUCAI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>MMX Mesalamine/Mesalazine (Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, tablets - the amount depends on the subjects weight&lt;br&gt;&amp;lt;br&amp;gt;-900 mg/day for subjects weighing 18 to less than or equal to 23kg&lt;br&gt;&amp;lt;br&amp;gt;-1200 mg/day for subjects weighing &amp;gt;23 to less than or equal to35kg&lt;br&gt;&amp;lt;br&amp;gt;-1800 mg/day for subjects weighing &amp;gt;35 to less than or equal to 50kg&lt;br&gt;&amp;lt;br&amp;gt;-2400 mg/day for subjects weighing &amp;gt;50 to less than or equal to 90kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMX Mesalamine/Mesalazine (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, tablets - the amount depends on the subjects weight&lt;br&gt;&amp;lt;br&amp;gt;&lt;br&gt;&amp;lt;br&amp;gt;•1800 mg/day for subjects weighing 18 to less than or equal to 23kg&lt;br&gt;&amp;lt;br&amp;gt;•2400 mg/day for subjects weighing &amp;gt;23 to less than or equal to35kg&lt;br&gt;&amp;lt;br&amp;gt;•3600 mg/day for subjects weighing &amp;gt;35 to less than or equal to 50kg&lt;br&gt;&amp;lt;br&amp;gt;•4800 mg/day for subjects weighing &amp;gt;50 to less than or equal to 90kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMX Mesalamine/Mesalazine (Low Dose)</intervention_name>
    <description>Once daily, tablets - the amount depends on the subjects weight&lt;br&gt;&amp;lt;br&amp;gt;-900 mg/day for subjects weighing 18 to less than or equal to 23kg&lt;br&gt;&amp;lt;br&amp;gt;-1200 mg/day for subjects weighing &amp;gt;23 to less than or equal to35kg&lt;br&gt;&amp;lt;br&amp;gt;-1800 mg/day for subjects weighing &amp;gt;35 to less than or equal to 50kg&lt;br&gt;&amp;lt;br&amp;gt;-2400 mg/day for subjects weighing &amp;gt;50 to less than or equal to 90kg.</description>
    <arm_group_label>MMX Mesalamine/Mesalazine (Low Dose)</arm_group_label>
    <other_name>Lialda</other_name>
    <other_name>Mezavant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMX Mesalamine/Mesalazine (High Dose)</intervention_name>
    <description>Once daily, tablets - the amount depends on the subjects weight&lt;br&gt;&amp;lt;br&amp;gt;&lt;br&gt;&amp;lt;br&amp;gt;•1800 mg/day for subjects weighing 18 to less than or equal to 23kg&lt;br&gt;&amp;lt;br&amp;gt;•2400 mg/day for subjects weighing &amp;gt;23 to less than or equal to35kg&lt;br&gt;&amp;lt;br&amp;gt;•3600 mg/day for subjects weighing &amp;gt;35 to less than or equal to 50kg&lt;br&gt;&amp;lt;br&amp;gt;•4800 mg/day for subjects weighing &amp;gt;50 to less than or equal to 90kg.</description>
    <arm_group_label>MMX Mesalamine/Mesalazine (High Dose)</arm_group_label>
    <other_name>Mezavant</other_name>
    <other_name>Lialda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to voluntarily provide written, signed, and dated (personally or via a legally
             authorized representative [LAR]) informed consent or assent as applicable to
             participate in the study.

          2. Subject's parent/LAR demonstrates an understanding, ability, and willingness to fully
             comply with study procedures and restrictions.

          3. Male and female children and adolescents aged 5-17 years, inclusive.

          4. Body weight 18-90kg.

          5. Male, or non-pregnant, non-lactating female who agrees to comply with any applicable
             contraceptive requirements of the protocol or females of non-childbearing potential.

          6. Diagnosed with mild to moderate UC, established by sigmoidoscopy or colonoscopy with
             compatible histology. Screened subjects may also have an unconfirmed diagnosis of mild
             to moderate UC; however the diagnosis of mild to moderate UC must have been
             established by sigmoidoscopy or colonoscopy with compatible histology prior to
             baseline visit.

          7. Subject is able to swallow the investigational product whole.

             Double-blind Acute Phase:

          8. Partial UC-DAI score ≥2 (a combined rectal bleeding and stool frequency score ≥1 and
             PGA=1 or 2) at the Baseline Visit, for which 5-ASA would be used as part of normal
             treatment.

          9. If the subject is on 5-ASA treatment prior to study entry, then the dose must be
             stable. Stable therapy is defined as no change in dose, or no initiation of 5-ASA,
             from the onset of the current acute flare through discontinuation of therapy (required
             at the Baseline Visit).

             Double-blind Maintenance Phase:

         10. Partial UC-DAI ≤1 (rectal bleeding=0, stool frequency ≤1, and PGA=0) at the Baseline
             Visit.

        Exclusion Criteria:

          1. Severe UC (defined by PGA=3).

          2. Crohn's disease, bleeding disorders, active peptic ulcer disease, or UC known to be
             confined to the rectum (isolated rectal proctitis).

          3. Asthma, only if known to be 5 ASA sensitive.

          4. Positive stool culture for enteric pathogens (including Salmonella, Shigella,
             Yersinia, Aeromonas, Plesiomonas, or Campylobacter). Clostridium difficile toxin, ova,
             or parasites present.

          5. Systemic or rectal corticosteroid use within 4 weeks prior to the Screening Visit.
             Topical, intranasal, or inhaled use is not exclusionary.

          6. Immunomodulator (6-mercaptopurine, azathioprine) use within 6 weeks prior to the
             Screening Visit.

          7. History of biologic (eg, anti-tumor necrosis factor agents, integrin receptor
             antagonists) use at any time.

          8. Antibiotic use within 7 days prior to the Screening Visit.

          9. Any anti-inflammatory drugs, not including 5-ASA treatment but including non-steroidal
             anti-inflammatory drugs such as aspirin, COX-2 inhibitors or ibuprofen, within 7 days
             prior to the Screening Visit unless used at over-the-counter levels for &lt;3 days.
             However, prophylactic use of a stable dose of aspirin up to 325mg/day for cardiac
             disease is permitted.

         10. Prebiotic/probiotic use within 7 days prior to the Screening Visit. Yogurt products
             are permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <email>clinicaltransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Tilme</last_name>
      <phone>407-786-9715</phone>
      <email>Linda.Tilme@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Bornstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Johnson</last_name>
      <email>krjohnson@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Children's Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenica Kochergin</last_name>
      <phone>781-727-7729</phone>
      <email>ekochergin@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Harland Winter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newton Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Washek</last_name>
      <phone>617-243-5855</phone>
      <email>MAWASHEK@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Harland Winter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Children's Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Gastroenterology</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwen Boe</last_name>
      <phone>507-266-9917</phone>
      <email>Boe.Gwen@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>William Faubion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Reynoso</last_name>
      <phone>212-305-6274</phone>
      <email>er2564@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ali Mencin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takyah Wilson</last_name>
      <phone>214-456-9238</phone>
      <email>takiyah.wilson@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Ashish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angilique Falcon</last_name>
      <phone>817-310-4489</phone>
      <email>AFalcon@tddctx.com</email>
    </contact>
    <investigator>
      <last_name>Manisha Dave</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carilion Medical Center</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Florow</last_name>
      <phone>540-224-6751</phone>
      <email>cmflorow@carilionclinic.org</email>
    </contact>
    <investigator>
      <last_name>Michael Hart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Pediatric Gastroenterology &amp; Nutrition</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faye Murdoch</last_name>
      <phone>1-780-248-5610</phone>
      <email>faye.murdoch@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Matthew Carroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Korányi</city>
        <state>Szeged</state>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Rozsa</last_name>
      <phone>+36 20 216 7767</phone>
      <email>rozsapetra@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Csaba Bereczki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szent Janos Korhaz És Észak-budai Egyesitett Korha</name>
      <address>
        <city>Budapest</city>
        <zip>H-1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Pandy Kalman Korhaz</name>
      <address>
        <city>Gyula</city>
        <zip>H-5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kolozsi, MD</last_name>
      <phone>+36 20 265 0065</phone>
      <email>kolani@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Piroska Bodi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktato Korhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Nagy</last_name>
      <phone>+36 30 535 5868</phone>
      <email>dnagyrita@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ferenc Dicso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>85025</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maka Titiashvili</last_name>
      <phone>972-8-6244245</phone>
      <email>maka@bgu.ac.il</email>
    </contact>
    <investigator>
      <last_name>Baruch Yerushalmi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Corporation</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anat Ronia</last_name>
      <phone>972-50-2063813</phone>
      <email>a_ronai@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ron Shaoul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thila Ben Moshe</last_name>
      <phone>972-2-5645028</phone>
      <email>tahilabm@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Raffi Lev-Zion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Medical Centre</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reut Klein</last_name>
      <phone>972-3-9253376</phone>
      <email>reutkl@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Amit Assa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emma Kinderziekenhuis AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faiza Khawaja</last_name>
      <phone>+31 20 566 8000</phone>
      <email>f.k.khawaja@amc.nl</email>
    </contact>
    <investigator>
      <last_name>Angelika Kindermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jos Gilissen</last_name>
      <phone>+31243615035</phone>
      <email>j.gilissen@cukz.umcn.nl</email>
    </contact>
    <investigator>
      <last_name>G Damen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ERASMUS MC Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Isala Ziekenhuis - Amalia Kindercentrum</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Dzieciecy Szpital Kliniczny im. Ludwika Zamenhofa</name>
      <address>
        <city>Bialystok</city>
        <zip>15-247</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miroslawa Uscinowicz</last_name>
      <phone>+48857450706</phone>
      <email>mirusc@o2.pl</email>
    </contact>
    <investigator>
      <last_name>Dariusz Lebensztejn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Copernicus Podmiot Leczniczy sp. z o.o</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Radys</last_name>
      <phone>48 587640239</phone>
      <email>wradys@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Landowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Pediatrii Gastroenterologii I Zywienia</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Sikora</last_name>
      <phone>+48 126574012</phone>
      <email>sikorka4@o2.pl</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Fyderek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Gastroenterologii I Pediatrii</name>
      <address>
        <city>Lodz</city>
        <zip>93-316</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Sordyl</last_name>
      <phone>+48-42-271-13-49</phone>
      <email>beatasordyl@op.pl</email>
    </contact>
    <investigator>
      <last_name>Elzbieta Czkwianianc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital Dzieciecy</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Daukszewicz</last_name>
      <phone>+48 895393462</phone>
      <email>adauk@mp.pl</email>
    </contact>
    <investigator>
      <last_name>Elizabeta Jarocka-Cyrta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski-Bartosz Korczowski</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Trela</last_name>
      <phone>+48 (17)8664141</phone>
      <email>anna-grad@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Bartosz Korczowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Dzieciercy Szpital Kliniczny</name>
      <address>
        <city>Warszawa</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Oddzial Gastroenterologii I Hepatologii</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Matuszczyk</last_name>
      <phone>+ 48508102296</phone>
      <email>gosiam86@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jaroslaw Kierkus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny N 1</name>
      <address>
        <city>Wrocław</city>
        <zip>50-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Matusiewicz</last_name>
      <phone>+48 664 722 160</phone>
      <email>vermer20@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Barbara Iwanczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Detská fakultná nemocnica s poliklinikou</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 09</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Hlavata, MD</last_name>
      <phone>+421 902106179</phone>
      <email>katarina.hlavata@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Iveta Cierna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univerzitna Nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>LI2 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Morrcroft</last_name>
      <phone>+44 0151 228 4811</phone>
      <email>theresa.moorcroft@alderhey.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Steve Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust, Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilarious (Harry) De Jesus</last_name>
      <phone>+44 020-359-41455</phone>
      <email>Hilarious.DeJesus@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nick Croft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Dickson</last_name>
      <phone>+44-02-0-3299 2129</phone>
      <email>holly.dickson@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Babu Vadammalayan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Godwin</last_name>
      <phone>+44 0207 405 9200</phone>
      <phone_ext>1242</phone_ext>
      <email>heather.godwin@gosh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Febronia Kiparissi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild</keyword>
  <keyword>Moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

